Skip to main
MMSI

MMSI Stock Forecast & Price Target

MMSI Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Merit Medical Systems is well positioned to sustain mid-single digit organic revenue growth and double-digit EPS growth because its Cardiovascular-led portfolio benefits from new product launches, acquisitions, pricing actions, and cost reduction efforts. The company is tracking to a roughly 6.6% organic revenue CAGR for 2024-2026, versus a 5%-7% target, while consensus implies a 2026 adjusted operating margin of 21.2% and cumulative free cash flow of $634M, both above the original CGI plan. With healthy U.S. and European demand, improving China trends, and early signs of a higher-growth therapeutic mix shift, its margin expansion and cash generation appear durable even amid tariff headwinds.

Bears say

Merit Medical Systems is facing a negative outlook because the forecast improvement in gross margin from 50.4% in 2023A to 54.0% in 2026E is being partly offset by rising SG&A to 27.0% of sales, leaving operating leverage dependent on execution that could disappoint. The bear case already assumes revenue growth of 5% or lower, driven by weaker acquisition growth and unsuccessful new product launches, which could trigger further margin contraction and below-consensus earnings. Although 1Q26 free cash flow improved to $25M and net leverage stayed at 1.6x, risks such as margin pressure, slower China growth, and acquisition integration remain significant.

MMSI has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merit Medical Systems (MMSI) Forecast

Analysts have given MMSI a Buy based on their latest research and market trends.

According to 8 analysts, MMSI has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $98.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $98.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merit Medical Systems (MMSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.